According to the sources, Trump officials discuss tightening curbs on Nvidia (NVDA.US) sales to China, after DeepSeek release. Bloomberg reported that officials had very early talks about restricting the H20 chip, which Nvidia designed as a 'scaled-down' product for the Chinese market. The markets see this information as a confirmation that DeepSeek is a 'real deal' and some revenues of the AI infrastructure providers may be at risk, due to Chinese sales curbs, and maybe by also somehow different approach, more cost-effective approach to developing AI capabilities. In the past four quarters, Nvidia's China revenue reached $13.5 billion from fiscal Q4 2024 to fiscal Q3 2025; the 12% of the company's total sales. Down from 21% a year earlier, but still a significant number.
Source: xStation5
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appThe material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
